See more : GrowGeneration Corp. (GRWG) Income Statement Analysis – Financial Results
Complete financial analysis of Alvotech (ALVO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Alvotech, a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- Takagi Seiko Corporation (4242.T) Income Statement Analysis – Financial Results
- PT Dana Brata Luhur Tbk (TEBE.JK) Income Statement Analysis – Financial Results
- AB Science S.A. (ABSCF) Income Statement Analysis – Financial Results
- HealthWarehouse.com, Inc. (HEWA) Income Statement Analysis – Financial Results
- White Label Liquid, Inc. (WLAB) Income Statement Analysis – Financial Results
Alvotech (ALVO)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.alvotech.com
About Alvotech
Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company's lead program is AVT02, a high concentration formulation biosimilar to Humira to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT04, a biosimilar to Stelara to treat various inflammatory conditions comprising psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT06, a biosimilar to Eylea to treat various conditions, such as age-related macular degeneration, macular edema, and diabetic retinopathy; and AVT03, a biosimilar to Xgeva and Prolia, which is in the pre-clinical phase to treat prevent bone fracture, spinal cord compression, and the need for radiation or bone surgery in patients with certain types of cancer, as well as prevent bone loss and increase bone mass. It also offers AVT05, a biosimilar to Simponi and Simponi Aria, which is in early phase development to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, and other indications; AVT16, a biosimilar to an immunology product; AVT23, a biosimilar to Xolair, which is in late-stage development to treat nasal polyps; and AVT33, a biosimilar to an oncology product. The company was founded in 2013 and is headquartered in Reykjavik, Iceland.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 91.43M | 83.03M | 36.77M | 66.62M | 31.92M |
| Cost of Revenue | 160.86M | 64.10M | 0.00 | 0.00 | 0.00 |
| Gross Profit | -69.42M | 18.93M | 36.77M | 66.62M | 31.92M |
| Gross Profit Ratio | -75.93% | 22.80% | 100.00% | 100.00% | 100.00% |
| Research & Development | 210.83M | 180.62M | 191.01M | 148.07M | 95.56M |
| General & Administrative | 76.56M | 186.74M | 84.13M | 58.91M | 48.57M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 76.56M | 186.74M | 84.13M | 58.91M | 48.57M |
| Other Expenses | -1.95M | -1.99M | -2.91M | -2.83M | -50.76M |
| Operating Expenses | 285.44M | 365.38M | 272.23M | 204.15M | 93.37M |
| Cost & Expenses | 446.46M | 429.47M | 272.23M | 204.15M | 93.37M |
| Interest Income | 4.82M | 2.55M | 51.57M | 215.00K | 1.74M |
| Interest Expense | 134.82M | 188.42M | 117.36M | 97.47M | 95.76M |
| Depreciation & Amortization | 24.21M | 20.41M | 18.20M | 16.42M | 14.61M |
| EBITDA | -484.86M | -439.80M | 3.99M | -125.67M | -99.02M |
| EBITDA Ratio | -530.29% | -392.72% | -457.17% | -188.65% | -150.74% |
| Operating Income | -354.86M | -346.44M | -235.46M | -137.54M | -61.45M |
| Operating Income Ratio | -388.11% | -417.25% | -640.31% | -206.46% | -192.52% |
| Total Other Income/Expenses | -296.19M | -205.21M | 86.26M | -154.23M | -147.94M |
| Income Before Tax | -651.05M | -551.65M | -149.20M | -291.77M | -209.39M |
| Income Before Tax Ratio | -712.04% | -664.40% | -405.74% | -437.99% | -656.01% |
| Income Tax Expense | -99.32M | -38.07M | -47.69M | -121.73M | 491.00K |
| Net Income | -551.73M | -513.58M | -101.50M | -170.04M | -209.88M |
| Net Income Ratio | -603.42% | -618.55% | -276.04% | -255.26% | -657.55% |
| EPS | -2.43 | -2.60 | -3.25 | -5.44 | -0.86 |
| EPS Diluted | -2.43 | -2.60 | -3.25 | -5.44 | -0.86 |
| Weighted Avg Shares Out | 227.26M | 197.72M | 31.25M | 31.25M | 243.65M |
| Weighted Avg Shares Out (Dil) | 227.26M | 197.72M | 31.25M | 31.25M | 243.65M |
Alvotech and Teva Announce U.S. FDA Approval of SELARSDI™ (ustekinumab-aekn), biosimilar to Stelara® (ustekinumab)
Alvotech and Teva Announce U.S. FDA Approval of SELARSDI™ (ustekinumab-aekn), biosimilar to Stelara® (ustekinumab)
Alvotech Hosts Audio Call for Investors at 8:15 am EDT on April 3, 2024
Alvotech Hosts Audio Call for Investors at 8:15 am EDT on April 3, 2024
Alvotech Announces Increase in Number of Own Shares
Alvotech Announces Increase in Number of Own Shares
Alvotech (ALVO) Q4 2023 Earnings Call Transcript
Alvotech Reports Financial Results for Full Year 2023 and Provides a Business Update
Alvotech Reports Financial Results for Full Year 2023 and Provides a Business Update
Alvotech Announces Webcast of Full Year 2023 Financial Results on March 21, 2024, at 8:00 am ET
Source: https://incomestatements.info
Category: Stock Reports